INABMEDIUM SIGNALFINANCIAL10-K

INAB executed a 1-for-30 reverse stock split and significantly improved its financial position with current assets increasing 122% while reducing operating losses by 36%.

The reverse stock split typically signals the company was approaching minimum listing requirements, suggesting prior financial distress. However, the substantial improvement in cash position and reduced burn rate indicates either successful fundraising or cost management initiatives that have stabilized the business in the near term.

Comparing 2026-03-12 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

INAB's financial metrics show a dramatic turnaround with current assets more than doubling to $27.9M while liabilities decreased 27%, suggesting successful capital raising or asset optimization. Operating cash flow burn improved significantly from -$24.1M to -$12.7M, and R&D expenses were cut 40% from $17.0M to $10.2M, indicating more disciplined spending. The overall picture suggests the company has bought itself time through improved liquidity and cost controls, though the reverse stock split indicates it faced significant equity price pressure during the period.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+121.7%
$12.6M$27.9M

Current assets grew 121.7% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+90.3%
$14.5M$27.6M

Equity base grew 90.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+54.1%
$20.9M$32.3M

Asset base grew 54.1% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
+47.4%
-$24.1M-$12.7M

Operating cash flow surged 47.4% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-39.8%
$17.0M$10.2M

R&D spending cut 39.8% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+36.1%
-$30.4M-$19.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+36.1%
-$30.4M-$19.4M

Net income grew 36.1% — bottom-line growth signals improving overall business health.

Total Liabilities
Balance Sheet
-26.9%
$6.5M$4.7M

Liabilities reduced 26.9% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-13
ADDED
The images found on pages 9, 10, 15, 21, 27 and 29 of this Annual Report were created with biorender.com.
Unless otherwise indicated, all information in this Annual Report on Form 10-K gives effect to the 1-for-30 reverse stock split of our common stock that became effective on June 5, 2025, and all references to shares of common stock outstanding and per share amounts give effect to the reverse stock split.
These cells serve as a functional bridge between innate and adaptive immunity, contributing to direct tumor-killing as well as immune cell recruitment and activation to drive deeper, more comprehensive immune responses.
Our platform employs allogeneic, autologous, induced pluripotent stem cell ("iPSC") and genetically modified cell therapy approaches, as well as TCEs that are designed to effectively identify and eradicate tumor or target cells.
We believe this lofty aspiration will one day be achievable and that it is our responsibility to directly contribute to global health efforts by pursuing scientific research that will advance the treatment of cancer and other diseases with unmet medical needs.
+7 more — sign up free →
REMOVED
The images found on pages 7, 9, 13, 19, 24, 26 and 27 of this Annual Report were created with biorender.com.
These cells serve as a functional bridge between innate and adaptive immunity to contribute to direct tumor-killing, as well as immune cell recruitment and activation to drive deeper and more comprehensive immune responses.
Our platform employs allogeneic, autologous, induced pluripotent stem cell ("iPSC"), genetically modified cell therapy approaches, and TCEs that are designed to effectively identify and eradicate tumor and targeted cells.
We believe this lofty aspiration will one day be achievable, and that it is our responsibility to directly contribute to related global health efforts by pursuing scientific research that will advance the treatment of cancer and other diseases with unmet needs Our DeltEx platform is designed to overcome many of the challenges associated with the expansion, genetic engineering, and scalable manufacturing of gamma-delta T cells.
We currently have two novel programs in the clinic that have demonstrated durable complete tumor remissions.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →